Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 560.00M | 121.00M | 90.00M | 41.00M | 27.00M |
Gross Profit | 432.00M | 108.00M | 90.00M | 41.00M | 27.00M |
EBITDA | -2.54B | -2.70B | -4.52B | -3.61B | -3.97B |
Net Income | -4.24B | -3.82B | -5.17B | -4.91B | -5.51B |
Balance Sheet | |||||
Total Assets | 14.19B | 15.15B | 15.03B | 23.97B | 23.17B |
Cash, Cash Equivalents and Short-Term Investments | 3.67B | 6.72B | 7.32B | 15.13B | 13.92B |
Total Debt | 2.66B | 4.53B | 7.15B | 11.96B | 11.40B |
Total Liabilities | 12.11B | 11.29B | 10.65B | 15.33B | 15.32B |
Stockholders Equity | 2.06B | 3.86B | 4.38B | 8.64B | 7.84B |
Cash Flow | |||||
Free Cash Flow | -1.83B | -2.85B | -4.86B | -5.39B | -4.26B |
Operating Cash Flow | -1.82B | -2.82B | -4.60B | -5.09B | -3.94B |
Investing Cash Flow | -1.42B | -1.12B | -909.00M | -736.00M | -1.22B |
Financing Cash Flow | 77.00M | 3.34B | -2.50B | 6.99B | 803.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | ¥25.38B | ― | ― | -2.34% | -278.32% | ||
52 Neutral | $7.60B | 0.11 | -62.95% | 2.07% | 16.16% | 0.31% | |
51 Neutral | ¥78.04B | ― | ― | 374.19% | 35.53% | ||
49 Neutral | ¥20.00B | 201.62 | ― | 8.46% | 49.97% | ||
47 Neutral | ¥19.32B | ― | ― | -100.00% | -1079.89% | ||
46 Neutral | ¥16.81B | ― | ― | -4.04% | -0.88% | ||
33 Underperform | ¥51.21B | ― | ― | -12.82% | -19.87% |
Healios K.K. has been selected for a JPY 7 billion subsidy under Japan’s METI program to support capital investment in regenerative, cell, and gene therapy manufacturing facilities. This funding will enable Healios to expand its CDMO business, enhancing its competitive edge in the global market by integrating advanced technologies and establishing a robust international platform. The initiative aligns with Japan’s industrial policy and aims to strengthen Healios’s position as a leader in regenerative medicine, fostering new partnerships and enhancing shareholder value.
The most recent analyst rating on (JP:4593) stock is a Buy with a Yen320.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.